PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.23%
Negative revenue growth while 3141.T stands at 2.42%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
4.03%
Positive gross profit growth while 3141.T is negative. John Neff would see a clear operational edge over the competitor.
16.71%
EBIT growth above 1.5x 3141.T's 1.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
10.30%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
4.09%
Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.
4.08%
Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
4.08%
Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3141.T is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.09%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.09%
10Y revenue/share CAGR under 50% of 3141.T's 164.52%. Michael Burry would suspect a lasting competitive disadvantage.
71.44%
5Y revenue/share CAGR at 75-90% of 3141.T's 80.03%. Bill Ackman would encourage strategies to match competitor’s pace.
36.36%
3Y revenue/share CAGR similar to 3141.T's 38.76%. Walter Schloss would assume both companies experience comparable short-term cycles.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.81%
Below 50% of 3141.T's 491.30%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
122.26%
Below 50% of 3141.T's 245.12%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
61.49%
3Y net income/share CAGR 1.25-1.5x 3141.T's 52.11%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
198.97%
10Y equity/share CAGR at 50-75% of 3141.T's 277.11%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
124.19%
5Y equity/share CAGR 1.25-1.5x 3141.T's 86.48%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
57.00%
3Y equity/share CAGR 1.25-1.5x 3141.T's 38.87%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Firm’s AR is declining while 3141.T shows 1.22%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.29%
Inventory shrinking or stable vs. 3141.T's 10.03%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-1.54%
Negative asset growth while 3141.T invests at 4.71%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.33%
BV/share growth above 1.5x 3141.T's 2.37%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-44.81%
We’re deleveraging while 3141.T stands at 4.47%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
89.49%
SG&A growth well above 3141.T's 31.65%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.